TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proved breast cancer~* Relapse/recurrent brain metastasis progression after brain radiotherapy~* Presence of brain measurable disease which is defined as at least one brain lesion that can be measured in at least 1 dimension as ³ 20 mm with magnetic resonance image (MRI)~* Prior chemotherapy or hormone therapy for metastatic breast cancer is allowed~* Performance status of ECOG 0, 1, 2~* With normal left ventricular ejection fraction and normal ventricular contractility~* Age 21 years or older~* Life expectancy equal or longer than 3 months~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Prior anthracycline-containing chemotherapy with cumulative dose exceed 400mg/m2 doxorubicin or 750 mg/m2 Epirubicin~* Surgery , radiotherapy, hormonal therapy or chemotherapy within 4 weeks prior to entering the study~* Prior liposomal doxorubicin treatment~* Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period~* Other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study~* Brain metastases defined as meninges metastases~* Presence of serious concomitant illness which might be aggravated by study medication:~  * Uncontrolled infection (active serious infections that are not controlled by antibiotics)~ * Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study.~ * History of ventricular arrhythmia or congestive heart failure.~* Presence of abnormal left ventricular ejection fraction~* Hematopoietic function as defined below:~  * Hemoglobin\<10g/dl~ * ANC\< 1,500/uL~ * Platelets\<100,000/uL~* Organ function as defined below:~  * Total bilirubin \>1.5 × ULN~ * ALT / AST\>3 × ULN (\>5.0 x ULN if hepatic metastasis)~ * Creatinine \>1.5 × ULN~* Mental status is not fit for clinical trial~* Pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial Evaluating the Effect of Closed Suction Drainage Versus Straight Drainage After Distal Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing distal pancreatectomy at Johns Hopkins Hospital~Exclusion Criteria:~* Children \<18 years old, pregnant women, adults lacking capacity to consent, non-english speakers, and prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Soft Pancreatic Gland (Type: OTHER): This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
- Hard Pancreatic Gland (Type: OTHER): This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age and has successfully completed Keryx Study 101-301.~* Diagnosis of DM2 based on ADA criteria.~* Continued stable seated systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 90 mmHg.~* Provide written informed consent to participate in the study.~* If female and of childbearing potential, must continue to be willing to use adequate contraception, as determined by the investigator, for the duration of the study.~Exclusion Criteria:~* Evidence of hepatic dysfunction including total bilirubin \> 2.0 mg/dL (34 micromol/L) or liver enzymes \> 3 times upper limit of normal.~* Unstable angina pectoris or New York Heart Association Class III or IV congestive heart failure.~* A history of any major medical condition, including but not limited to: aortic aneurysm; myocardial infarction, stroke, or other cardiovascular events in the past 3 months; gastrointestinal bleeding in the past 3 months; HIV; and other medical conditions deemed serious by the investigator. Active Hepatitis B or C (currently active disease defined as an abnormal liver biopsy or persistent, elevated transaminases, SGOT, SGPT).~* Any risk of bleeding, including a history of bleeding diathesis and a platelet count \< 100,000/mm³.~* Active or metastatic cancer (note: superficial basal carcinoma of the skin is not an exclusion).~* Anticipated surgery within trial period.~* History of noncompliance to medical regimens in Keryx Study No.101-301.~* Participation in any experimental drug study in the past 60 days, except for KRX-101-301, prior to entry into the study, or plan to participate in any experimental drug study during the study period.~* Lactation, pregnancy, or an anticipated or planned pregnancy during the study period.~* Known allergy or intolerance to any heparin-like compounds.~* Patients with other specific renal diseases known to be the cause of nephropathy, and patients with other specific, clinically significant renal disease.~* Inability to give an informed consent or cooperate with the study personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sulodexide (Type: EXPERIMENTAL): Open label extension to original trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Monocenter Prospective Study to Evaluate the Efficacy of Peripherally Inserted Central Catheter to Tunnelled Central Catheter With Cuff in Home Parenteral Nutrition for Long-term Used.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years-old~* Patients managed by CHU Nice for home parenteral nutrition~* Expected to have over 1 month of parenteral nutrition~* Signed consent~* Affiliation to Securite Social~Exclusion criteria~* Patient with nutritional catheter before inclusion~* Pregnancy or breastfeeding~* Evolutive pathology with life expectancy \< 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group B (Type: ACTIVE_COMPARATOR): After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
- Group A (Type: EXPERIMENTAL): PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Patients who had received a kidney, liver, lung or heart transplant more than 3 years prior to inclusion into the study~* Patients who had been treated at least 6 months prior to study entry with a stable twofold or threefold immunosuppressive treatment~* Patients who had clinically confirmed epithelial dysplasia (actinic keratoses) in at least two anatomically separated contralateral areas on the face and/or scalp with comparable size and extension and minimum distance of 5 cm~Exclusion Criteria:~* Invasive squamous cell carcinoma or basal cell carcinoma in the treatment area~* Known allergy to imiquimod and/or methyl-aminolaevulinate and/or one of the other components of the investigational products and/or peanut oil~* Patients who have received retinoids, interferons or investigational drugs within 4 weeks of study initiation~* Patients who are participating in othe dermatological study~* Persistent Hepatitis B or C infections~* Any evidence of systemic cancer~* Patients who have received any systemic cancer chemotherapy or radiation therapy~* Pregnant or lactating women~* Patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- photodynamic therapy (Type: EXPERIMENTAL): Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann \& Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
- imiquimod 5% cream (Type: ACTIVE_COMPARATOR): 250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women~2. Ages 18-65~3. Have schizophrenia or schizoaffective disorder~4. Would like to quit smoking within the next 6 months~5. Have smoked at least 10 cigarettes per day in the past year~6. Have breath CO level \> 10 ppm~7. Able to speak, read and comprehend English well enough to complete study procedures~Exclusion Criteria:~1. Pregnant, breast-feeding, or unwilling to use medically-approved contraception~2. Currently using varenicline, bupropion or nicotine replacement therapy for smoking cessation~3. Medical disease that would preclude participation~4. Unstable psychiatric conditions~5. Body mass index (BMI) \< 15 or \> 38 kg/m2~6. Past-month suicidal intention, with or without a specific plan~7. Positive urine drug screen or breath alcohol level \> 0.01% at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* renal transplant within last 3 months~* serum phosphorus less than 2.0 mg/dl~* serum creatinine less than 2.0 mg/dl~Exclusion Criteria:~* sensitivity to cinacalcet~* use of amitryptiline, desipramine, itraconazole, ketoconazole~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cincalcet (Type: ACTIVE_COMPARATOR): cinacalcet will be titrated as needed to achieve serum phosphorus of \> 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mg/l.
- Control (Type: PLACEBO_COMPARATOR): subjects will receive placebo pill titrated as needed to achieve phosphorus \> 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mEq/l.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-90 years old~* Scheduled for cardiac surgery requiring cardiopulmonary bypass~* Written informed consent~Exclusion Criteria:~* Off-pump surgical procedures~* Anticipated deep hypothermic circulatory arrest~* Any contraindications to the proposed interventions including lidocaine allergy~* History of preoperative atrial fibrillation~* Baseline Screening revealing preexisting dementia or delirium~* Preoperative liver failure defined as Child-Pugh Score \> 6

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intravenous Lidocaine group
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PCOS as defined by NIH/NICHD criteria: 1) oligo- or amenorrhea (≤8 menstrual periods annually, persisting 2 years post menarche); 2) biochemical hyperandrogenism(HA), i.e.,elevated total or free testosterone concentration and/or clinical evidence of HA (defined as the presence of hirsutism); and 3) exclusion of secondary causes of ovulatory dysfunction and HA (including hyperprolactinemia, thyroid dysfunction, non-classical congenital adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency, Cushing syndrome, androgen secreting neoplasms, and androgenic/anabolic drug use).~* Inclusion criteria for adolescent and adult control subjects will include 1) normal menstrual periods (defined as regular cycles between 22-36 days in length); 2) normal serum androgens (total/free testosterone and dehydroepiandrosterone-sulfate \[DHEA-S\]); and 3) absence of clinical evidence of hyperandrogenism. Additionally, adolescent controls must be 2 years post menarche.~Exclusion Criteria:~* Diabetes mellitus~* Underlying endocrine, neurologic, and/or genetic syndromes leading to obesity~* Congenital heart disease or abnormal resting ECG~* Renal or hepatic disease~* History of rheumatologic disorders or malignancy~* Use of medications or dietary supplements known to affect insulin sensitivity (i.e. metformin, corticosteroids, and oral contraceptive pills), blood pressure, or cholesterol within 3 months of study participation~* Investigation drug use within 3 months of study participation~* Pregnancy~* Current tobacco use

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- PCOS adolescents (Type: None): Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
- PCOS women (Type: None): Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cases fulfilling WHO (World Health Organization) 2016 diagnostic criteria for MPN including: Chronic myeloid leukemia, BCR-ABL1-positive (BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product), Chronic neutrophilic leukemia (CNL), Polycythemia vera, Primary myelofibrosis prefibrotic/early stage, Primary myelofibrosis overt fibrotic stage, Essential thrombocythemia, Chronic eosinophilic leukemia, not otherwise specified (NOS) and Myeloproliferative neoplasm, unclassifiable.~* Age between 14 and 18 years old~* Patient accepts to sign inform consent~* ECOG (Eastern Cooperative Oncology Group) performance less than or equal 2~Exclusion Criteria:~* Patient not fulfilling the inclusion criteria.~* Vulnerable groups: pregnant, minors, prisoners will not be included.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 18F-FLT PET/CT (Type: EXPERIMENTAL): Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. \[18F\] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) \[18F\] FLT by intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Covid-19, Acute Myocardial Infarctions and Strokes in France

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~- Adults admitted in 2018, 2019 or 2020 in a French hospital for acute coronary syndrom or stroke~Exclusion criteria:~- None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 period (Type: None): Admissions from January to December 2020
- Control period (Type: None): Admissions from January 2018 to December 2019

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lactose-free Milk in Infants With Acute Diarrhea in a Developing Country

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants on artificial milk formula~* Presenting to the ED or pediatric clinics of the American University of Beirut Medical Center~* Chief complaint: acute gastroenteritis (three or more loose or liquid stools in 24 hours, for at least 24 hours, and not exceeding 2 weeks from presentation, with or without fever, vomiting, mucus or blood per stools).~Exclusion Criteria:~* Exclusively or partially breast-fed infants~* Severe dehydration requiring hospitalization

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Months
- Healthy Volunteers: f

Study Arms:
- Lactose-free milk (Type: EXPERIMENTAL): Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
- Regular infant milk (Type: NO_INTERVENTION): Regular infant milk formula and anti-diarrheic diet for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues